Modulation of the opioid growth factor ([Met5]-enkephalin)–opioid growth factor receptor axis: Novel therapies for squamous cell carcinoma of the head and neck
Article first published online: 16 MAY 2011
Copyright © 2011 Wiley Periodicals, Inc.
Head & Neck
Volume 34, Issue 4, pages 513–519, April 2012
How to Cite
McLaughlin, P. J., Stucki, J. K. and Zagon, I. S. (2012), Modulation of the opioid growth factor ([Met5]-enkephalin)–opioid growth factor receptor axis: Novel therapies for squamous cell carcinoma of the head and neck. Head Neck, 34: 513–519. doi: 10.1002/hed.21759
- Issue published online: 3 MAR 2012
- Article first published online: 16 MAY 2011
- Manuscript Accepted: 24 JAN 2011
- Manuscript Revised: 3 JAN 2011
- Manuscript Received: 18 NOV 2010
- Zagon/Kostel families
- cell proliferation;
The opioid growth factor (OGF)–OGF receptor (OGFr) axis is a constitutively expressed biologic pathway regulating cell proliferation of squamous cell carcinoma of the head and neck (SCCHN). This study investigated modulation of the OGF–OGFr system by (1) exogenous OGF, (2) upregulation of OGFr using imiquimod, or (3) intermittent opioid receptor blockade with a low dose of naltrexone on progression of established SCCHN.
Nude mice with visible human SCCHN SCC-1 tumors received (1) OGF or low-dose naltrexone either 1, 3, or 7 times/week or (2) imiquimod 1 or 3 times/week. Tumor growth and DNA synthesis were monitored.
OGF and low-dose naltrexone increased the latency from visible to measurable tumors up to 1.6-fold. OGF, low-dose naltrexone, and imiquimod treatment markedly reduced tumor volume and weight, and decreased DNA synthesis in tumors.
Modulation of the native OGF–OGFr regulatory network in SCCHN represents a novel nontoxic and highly efficacious approach for treatment of SCCHN. © 2011 Wiley Periodicals, Inc. Head Neck, 2012